Ascentage Pharma Group International American Depository Shares (AAPG) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Ascentage Pharma Group International American Depository Shares (NASDAQ: AAPG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $14.88 (-0.70% 1D, market cap $1.39B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AAPG ranks #340 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AAPG carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KRSA (Korsana Biosciences Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -5.7%, cap $1.38B) and OMER (Omeros Corporation) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.37B). Among the 5-stock peer group, AAPG leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).
For Ascentage Pharma Group International American Depository Shares (AAPG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #340 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 1% FCF Margin ($38.9M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While AAPG currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.82) and Max Pain ($15.62) forces dealer call-delta covering toward $36.23.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Ascentage Pharma Group International American Depository Shares (AAPG) slipped -0.70% to $14.88, trading at 4% of its 52-week range ($13.99 – $34.5). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.
ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development an
Ascentage Pharma Group International has seen its share price move sharply in recent years, yet the current level still leaves a straightforward question for investors who care about fundamentals. Is the price you see on
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AAPG today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AAPG. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Ascentage Pharma Group International American Depository Shares (AAPG) ranks #340 by composite RQD confidence (47/100, grade D) and #312 by equity capitalization ($1.39B). Within this direct 5-issuer industry benchmark cohort, AAPG leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ANAB currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with AAPG at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AAPG
ACTIVE
Ascentage Pharma Group International American Depository Shares | D | 47/100 | — | — | — | -0.70% | $1.39B | Benchmark Subject |
| KRSA Korsana Biosciences Inc. | D- | 38/100 | — | — | -5.7% | +0.37% | $1.38B | /krsa-vs-aapg → |
| OMER Omeros Corporation | D | 46/100 | — | — | -35.0% | +5.98% | $1.37B | /omer-vs-aapg → |
| DMRA Damora Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | +1.85% | $1.36B | /dmra-vs-aapg → |
| ANAB AnaptysBio Inc. | C- | 60/100 | — | — | 85.0% | -3.68% | $1.44B | /anab-vs-aapg → |
Ascentage Pharma Group International American Depository Shares (AAPG) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.39B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Ascentage Pharma Group International American Depository Shares (NASDAQ: AAPG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $14.88 (-0.70% 1D, market cap $1.39B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AAPG ranks #340 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AAPG carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KRSA (Korsana Biosciences Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -5.7%, cap $1.38B) and OMER (Omeros Corporation) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.37B). Among the 5-stock peer group, AAPG leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).
For Ascentage Pharma Group International American Depository Shares (AAPG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #340 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
AAPG last traded at $14.88 (-0.70% on volume of 11,298 shares), positioning the stock -5.94% below its 50-day simple moving average ($15.82) and -25.90% below its 200-day simple moving average ($20.08). Across its 52-week range of $13.99 to $34.50, AAPG sits at the 4.3% percentile with a 14-day RSI of 46.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.8% ($13.87 to $15.89).
Why AAPG Stock slipped -0.70% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).